ArticleBMJ public health2026
C-reactive protein-triglyceride-glucose index and diabetic vascular complications risk among patients with diabetes: a national cohort study.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The C-reactive protein-triglyceride-glucose index (CTI) has emerged as an innovative biomarker for insulin resistance and inflammatory processes. Nevertheless, the association between CTI and diabetic vascular complications (DVCs) and its subtypes in individuals with diabetes remains unclear. Methods: This cohort study included 23 068 participants with diabetes from the UK Biobank at baseline (2006-2010). Cox proportional hazards models and restricted cubic splines (RCS) were employed to evaluate the associations of CTI and triglyceride-glucose-related indices with the risk of DVCs and its subtypes. Separate analyses were conducted for individuals with type 2 diabetes (T2D). The predictive performance of these indices was assessed using the net reclassification index (NRI) and Harrell's concordance index. Results: During a mean follow-up period of 13.3 years, 4089 (26.8%) individuals developed DVCs. A significant positive linear relationship was observed between CTI and the risk of incident DVCs. For 1 SD increase in CTI, the corresponding HRs (95% CIs) were 1.05 (1.02 to 1.11) for overall DVCs, 1.21 (1.16 to 1.27) for diabetic kidney disease, 1.19 (1.13 to 1.26) for diabetic retinopathy (DR), 1.34 (1.26 to 1.43) for diabetic neuropathy (DN), 1.22 (1.14 to 1.31) for peripheral artery disease (PAD) and 1.05 (1.00 to 1.10) for cardiovascular disease. RCS revealed approximately an inverse L-shaped relationship for DR, DN and PAD. The addition of CTI to the model significantly improved NRI and Harrell's concordance index for DVCs incidence. Conclusions: Our findings demonstrated a significant positive association between CTI and the incidence of DVCs in individuals with T1D and T2D. Furthermore, our study revealed dose-response relationships between CTI and all subtypes of DVCs, providing more comprehensive risk stratification information for individuals with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.